Literature DB >> 20523876

Docetaxel-induced photolichenoid eruption.

Biju Vasudevan1, M P S Sawhney, Nitu Sharma.   

Abstract

A 58-year-old man presented with complaints of blackish discoloration of forearms and face of five months duration. The lesions occurred episodically after taking anti-cancer medications, each episode lasting for two weeks. Histopathology confirmed a lichenoid eruption. Photolichenoid eruption to docetaxel is a dermatological adverse effect not reported in literature earlier.

Entities:  

Keywords:  Adverse effects; docetaxel; lichenoid eruption

Year:  2009        PMID： 20523876      PMCID： PMC2875744          DOI： 10.4103/0253-7613.56065

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN： 0253-7613            Impact factor:   1.200


  6 in total

Review 1.  Docetaxel: a review of its use in metastatic breast cancer.

Authors:  Katherine A Lyseng-Williamson; Caroline Fenton
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  The taxoids. Comparative clinical pharmacology and therapeutic potential.

Authors:  E A Eisenhauer; J B Vermorken
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

4.  Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

Authors:  J Guitton; S Cohen; B Tranchand; B Vignal; J-P Droz; M Guillaumont; M Manchon; G Freyer
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

5.  Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel.

Authors:  I Aydogan; A Kavak; A H Parlak; M Alper; A N Annakkaya; M Erbas
Journal:  J Eur Acad Dermatol Venereol       Date:  2005-05       Impact factor: 6.166

6.  New Agents in the Management of Non-Small Cell Lung Cancer.

Authors: 
Journal:  Cancer Control       Date:  1997-07       Impact factor: 3.302
  6 in total
  2 in total

1.  Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes.

Authors:  Gulsen Akoglu
Journal:  Indian J Pharmacol       Date:  2014 Mar-Apr       Impact factor: 1.200

2.  Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.

Authors:  Hazem Ghebeh; Adher Al-Sayed; Riham Eiada; Leilani Cabangon; Dahish Ajarim; Kausar Suleman; Asma Tulbah; Taher Al-Tweigeri
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.